Copyright
©2008 The WJG Press and Baishideng.
World J Gastroenterol. Jul 7, 2008; 14(25): 3937-3947
Published online Jul 7, 2008. doi: 10.3748/wjg.14.3937
Published online Jul 7, 2008. doi: 10.3748/wjg.14.3937
Table 1 Risk of colorectal cancer in recent population-based studies
Study | Location | Observed period | UC cohort size | Follow-up (person- years) | CRC | Annual crude incidence (%) | Cumulative incidence at 30 years (%) |
North America | |||||||
Bernstein et al[7] | Manitoba, Canada | 1984-1997 | 2672 | 19655 | 36 CRC | 0.16 | NR |
Bernstein et al[7] | Manitoba, Canada | 1984-1997 | 2672 | 19655 | 13 rectum | 0.06 | NR |
Jess et al[8] | Olmsted County, USA | 1940-2004 | 378 | 5567 | 6 | 0.10 | 2 |
Europe | |||||||
Winther et al[16] | Copenhagen County, Denmark | 1962-1987 | 1160 | 22290 | 13 | 0.06 | 2.1 |
Palli et al[15] | Florence, Italy | 1978-1992 | 689 | 7877 | 10 | 0.12 | NR |
Lakatos et al[4] | Veszprem, Hungary | 1974-2004 | 723 | 8564 | 13 | 0.15 | 7.5 |
Table 2 Summary of studies investigating the chemopreventive effect of sulfasalazine and 5-ASA therapies in ulcerative colitis
Study | Study design | n | Drug studies | Principal outcome |
Pinczowski et al[31] | Case-control | 298 | Sulfasalazine > 3 mo | ORCRC: 0.38 (95% CI, 0.2-0.69) patients administered sulfasalazine |
Moody et al[101] | Case-control | 175 | Sulfasalazine < 6 mo | 10-fold elevated risk in non-exposed patients (30% vs 3%) |
Eaden et al[40] | Case-control | 102 | Sulfasalazine, mesalasine regular use | ORCRC: 0.25 (95% CI, 0.13-0.48) in regular users |
Lindberg et al[102] | Cohort study | 143 | Sulfasalazine > 6 mo | Non-significant decrease of risk (34% vs 44%) |
Bernstein et al[87] | Case-control | 373 | 5-ASA | Non-significant elevation of risk in patients exposed |
Rutter et al[29] | Case-control | 204 | 5-ASA | Non-significant elevation of risk of dysplasia in patients exposed |
Rubin et al[90] | Case-control | 124 | 5-ASA > 1.2 g regular use | ORCRC: 0.28 (95% CI, 0.09-0.85) in regular users |
- Citation: Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies. World J Gastroenterol 2008; 14(25): 3937-3947
- URL: https://www.wjgnet.com/1007-9327/full/v14/i25/3937.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.3937